Deep Medicine Acquisition priced its upsized IPO of 11 million units at $10 each, an increase of 1 million more units than registered last month with the SEC.
Units are expected to list on the Nasdaq and begin trading today under DMAQU, 2021.
The SPAC intends to focus its search on targets in the healthcare industry with an enterprise value of approximately $500 million to $1 billion.
Deep Medicine is led by CEO and Chairman Humphrey P. Polanen, who is CEO and managing member of NeoVista Ventures, a private equity fund. Read more.
